Expert Perspectives on the Usage of Co-amoxiclav and Cefuroxime in Clinical Practice: A Cross-Sectional Survey from Indian Settings
Abstract
Background:
Although there are several clinical studies available regarding the management of bacterial infections, there is a dearth of studies among clinical experts on their practice. The survey aimed to assess clinical preferences and decision-making factors among clinicians regarding the use of co-amoxiclav and cefuroxime across a range of common infections and surgical indications in routine clinical practice in Indian settings.
Methodology:
This cross-sectional study was conducted among clinicians across India using a 22-item structured questionnaire. The questionnaire assessed common infection types, antibiotic usage patterns, indications for co-amoxiclav and cefuroxime, preferred regimens for community-acquired pneumonia (CAP), skin and soft tissue infections, and surgical prophylaxis, perceived comparative efficacy, factors influencing antibiotic choice, adverse drug reactions, and clinical outcomes using a global improvement scale. The data were analyzed using descriptive statistics.
Results:
Approximately 49% of clinicians identified streptococcal pharyngitis as the most common indication for recommending co-amoxiclav in routine practice. Nearly 60% reported co-amoxiclav as the most preferred empiric antimicrobial therapy for adult CAP in patients without comorbidities, while about 51% preferred it in patients with comorbidities. Around 76% of clinicians favored co-amoxiclav, with or without clindamycin, for the management of mild to moderate cellulitis in…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.